Psybio Therapeutics Corp Stock Last Dividend Paid
| PSYBF Stock | USD 0.0001 0.00 0.00% |
PsyBio Therapeutics Corp fundamentals help investors to digest information that contributes to PsyBio Therapeutics' financial success or failures. It also enables traders to predict the movement of PsyBio Pink Sheet. The fundamental analysis module provides a way to measure PsyBio Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PsyBio Therapeutics pink sheet.
PsyBio |
PsyBio Therapeutics Corp Company Last Dividend Paid Analysis
PsyBio Therapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, PsyBio Therapeutics Corp has a Last Dividend Paid of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Anywhere Now
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
PsyBio Fundamentals
| Return On Equity | -3.1 | |||
| Return On Asset | -0.98 | |||
| Current Valuation | 3.69 M | |||
| Shares Outstanding | 80.85 M | |||
| Shares Owned By Insiders | 25.61 % | |||
| Shares Owned By Institutions | 13.23 % | |||
| Price To Book | 202.42 X | |||
| Gross Profit | (1.56 M) | |||
| EBITDA | (10.91 M) | |||
| Net Income | (11.02 M) | |||
| Cash And Equivalents | 911.83 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 207.81 K | |||
| Debt To Equity | 7.03 % | |||
| Current Ratio | 0.89 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (6.95 M) | |||
| Earnings Per Share | (0.09) X | |||
| Market Capitalization | 4.94 M | |||
| Total Asset | 4.01 M | |||
| Z Score | 7.2 | |||
| Net Asset | 4.01 M |
About PsyBio Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PsyBio Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PsyBio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PsyBio Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in PsyBio Pink Sheet
PsyBio Therapeutics financial ratios help investors to determine whether PsyBio Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PsyBio with respect to the benefits of owning PsyBio Therapeutics security.